ELSEVIER

Contraception
1996;53:381–382

Author Index
Volume 53
January—June 1996

Adekunle, A.O., 121
Affandi, B., 121
Albert, A., 23
Allen, S., 329
Alvarez, F., 121
Amatya, R., 293
Amatya, R.N., 101
Andersch, B., 259
Araujo, F., 115
Archer, D.F., 329
Athayde, C., 37, 121

Bahamondes, L., 115
Balogh, A., 41
Barbosa, I., 37
Barbosa, I.C., 121
Bardin, C.W., 367
Bhargava, V.L., 127
Bhargava-Periwal, S., 127
Bhatla, N., 127
Bique, C., 243
Blohm, F., 259
Blumenthal, P., 329
Borm, G.F., 171
Börner, A., 41
Bottles, K., 97
Brache, V., 121
Budnick, L.E., 49
Bugalho, A., 243
Burkman, R., 197
Byström, B., 109

Carlos de Souza, J., 121
Carlström, K., 109
Carrasco, F., 23
Ceballos, G., 247
Chamorro, G., 247
Chan, Y.F., 281
Chandra, L., 363
Chen, X.-Q., 267
Chen, Z., 275
Chi, I-c., 101
Chompootaweep, S., 33
Chuang, S.-M., 177
Chun Wu, S., 357
Coenen, C.M.H., 171
Cooper, J., 329
Coutinho, E., 37
Coutinho, E.M., 121
Cowchock, F.S., 255
Creinin, M.D., 321
Cushman, L.F., 285

Darney, P.D., 97, 321
Davey, A., 345
Davidson, A.R., 285
de Lourdes Cristofoletti, M., 115
Deis, R.P., 185
Devoto, L., 121
Diabaté, F., 17
Diaz, J., 91
Diaz, M., 91
Diczfalusy, E., 1
Diez, M.J., 307
Doh, A., 293
Dominik, R., 329
Dueñas, J.L., 23
Dunson, T.R., 101
Dusitsin, N., 33
Düsterberg, B., 75

Ebi, K.L., 25
Ekwempu, C.C., 293
Emuveyan, E.E., 121
Endrikat, J., 75
Even, A., 49

Fahim, M.S., 231
Farmer, R.D.T., 211
Farooq, A., 127
Farr, G., 293
Faúndes, A., 91, 243
Fayed, A.-H.A., 181
Fernández, N., 307
Fingerhut, F., 329
Foldesy, R., 197
Frank, M.L., 147
Free, M.J., 221

Gabbay, M., 155
Gabelnick, H.L., 329
Garceau, R.J., 357
García, J.J., 307
Gibbs, A., 155
Glasier, A.F., 217
Glover, L.H., 329
Godsland, I.F., 9
Gordon, K., 55
Graff-Iversen, S., 337
Graham, J., 345
Grear, A., 147
Gu, Y., 275
Gupta, R.P., 363

Heartwell, S., 285
Heikinheimo, O., 55
Higgins, J.E., 85
Hirschberg, A.L., 109
Ho, P.C., 281
Hodgen, G.D., 55
Hollanders, J.M.G., 171

Indian Council of Medical
Research Task Force on
Natural Family Planning, 69

Jäger, R., 41
Jamisse, L., 243
Jiang, S., 357

Kalla, N.R., 299
Kalmuss, D., 285
Kaplan-Kraicer, R., 367
Katz, K., 17
Keder, L., 321
Kekkonen, R., 193
Kher, R., 299
Klaisle, C., 97
Klinger, G., 41
Ko, T.-M., 177
Kochagarn, E., 33
Koopersmith, T.B., 237
Kostovetsky, I., 367
Kotz, R., 221
Krueger, S.L., 101

Ladipo, O.A., 37, 121
Lähteenmäki, P., 193
Larsson, G., 259
Lali, P., 363
Lau, W., 281
Lawrenson, R., 211
Lee, T.-Y., 177
Lei, Z-W., 357
Levine, A.B., 255
Levine, H., 147, 353
Li, M.-X., 267
Liang, X., 275
Lidegaard, Ø., 135
Logan, J., 217
Lohiya, N.K., 375
Luo, L., 267
Lyszkowski, A.D.L., 141

Malamud, D., 313
Mango, D., 163
Manna, P., 163

© 1996 Elsevier Science Inc. All rights reserved.
655 Avenue of the Americas, New York, NY 10010

ISSN 0010-7824/96/$15.00
PII S0010-7824(96)00105-9

Contraception
1996;53:381–382

Marchi, N.M., 115
Maria, E., 243
Marlowe, D.E., 221
Mate, E.M., 17
Mateo de Acosta, O., 121
Mati, J., 121
Matthey, K., 41
Mauck, C., 329
McGlew, T.J., 217
McGough, B., 255
Meherji, P.K., 205
Mercer, D., 221
Miggiano, G.A.D., 163
Miller, E., 329
Milsom, I., 135, 259
Mishell, Jr., D.R., 197, 237
Morrison, C., 17
Mukherjee, S., 375
Munoz, O., 247
Murugesan, K., 127

Nakagava, H.M., 115

Olmos, P., 91
Olsson, S.-E., 37

Pal, R., 375
Peacock, L., 329
Peers, T., 345
Pellini, E., 115
Piziali, R.L., 25
Poindexter III, A.N., 147, 353
Pullum, T.W., 267

Reddy, K.V.R., 205
Reeves, K.O., 147
Ricci, S., 163
Rolland, R., 171
Rosenberg, M., 25
Rosenberg, M.J., 85, 141, 197
Rosenzweig, B.A., 49, 329
Rubin, J., 115
Rulin, M., 285
Ruminjo, J., 293
Ruminjo, J.K., 101

Sahagún, A.M., 307
Salazar, M., 247
Salazar, S., 247
Salem, H.T., 121
Sangi-Haghpeykar, H., 147, 353
Sarma, S.P., 159
Schindler, A.E., 75
Serra, G.B., 163
Shaaban, M.M., 121
Shahani, S.K., 205
Shalgi, R., 367
Sharma, M.G., 375
Shen, L., 275
Sierra, M., 307
Sirisumpan, S., 33
Solomon, H.M., 141
Speroff, L., 197
Srisamang, V., 221
Stensvold, I., 337
Stevens, J.E., 345
Storey, B.T., 313
Sturgen, K., 329

Talwar G.P., 375
Tang-usaha, J., 33
Taylor, R.N., 97
Telleria, C.M., 185
Teppa, J., 255
Terán, T., 307
Theppitaksak, B., 33
Thomas, C.M.G., 171
Thompson, K.A., 313
Tiller, G., 321
Toppozada, M., 293
Trujillo, J., 247
Tseng, L.-H., 177
Tverdal, A., 337

Ulmsten, U., 37
Usfá, M., 243

Vail, J., 221
Vander Meulen, T.C., 357
Vij, U., 127
Vittinghoff, E., 321
Vollanth, R., 41
von Schoultz, B., 109

Wachob, H.F., 25
Wamsher, J.G., 159
Wang, M., 231
Wang, W.-L., 357
Waszak, C., 17
Waugh, M.S., 85, 141, 197
Weber, A., 41
Whitlock, S.W., 159
Williams, R.F., 55
Winkler, U.H., 75
Wu, S.C., 357
Wu, S.-Z., 267

Yanez, R., 247
Yang, Q-Z., 357
Yang, Y.-S., 177

Zaloudek, C., 97
Zhi-Ping, G., 121
Zou, W., 275

ELSEVIER

Contraception
1996;53:383–385

Subject Index
Volume 53
January to June 1996

Acne lesions,
  effect of ethinylestradiol + desogestrel, 163
  effect of ethinylestradiol + gestodene, 163
Adolescents, contraception and pregnancy, 259
Advantage 24® spermicide, 147, 353
Aloe barbadensis, spermicidal effect, 231
Androgen levels, effect of nomegestrol acetate, 37
Androgens, effect of OCs, 171
Antifertility effects,
  buserelin (male mouse), 299
  (+)-S-amino-6-iodoacetamidohexanoic acid (rat), 247

Barrier contraceptive, Lea's Shield®, 329
Beliefs about Norplant implants, 285
Billings Ovulation Method, field trial, 69
Bioavailability of ethinylestradiol, effect of grapefruit juice, 41
Bleeding complaints, Norplant implants, 91
Bleeding patterns,
  effect of desogestrel, 85
  effect of gestodene, 85
  effect of levonorgestrel, 97
Body fat, effect of ethinylestradiol + desogestrel, 109
Buserelin, effect on spermatogenesis (mouse), 299

C31G anti-microbial agent, spermicidal activity, 313
Cardiovascular disease risk, effect of OC use, 9
Cardiovascular risk factors, OC users, CCC
Cardiovascular risk modifiers, effect of OC use, 9
Cholecystokinin level, effect of ethinylestradiol + desogestrel, 109
Clinical performance,
  Cu-Fix IUD, 197
  TCu 380A, 197, 293
Clinical trial,
  Norplant implants, 33, 101, 177
  Uniplant implant, 121
Coagulation system,
  effects of pregnancy, 255
  OC use, 255
Complications, induced abortions, 267
Conceptrol® spermicide, 147, 353
Condom failure, 155
Condoms,
  latex rubber, 221
  polyurethane, 141
  scanning electron microscopy, 49
Condoms and additional lubrication, 155
Consumer preference ratings, polyurethane vs. latex condoms, 141
Continuation rate, Norplant implants, 345
Contraception, postpartum, 217
Contraception and pregnancy, adolescents, 259
Contraceptive habits, women in 1981 vs. 1991, 259
Copper T 380A, postpartum insertion, 17
Counseling, effect on discontinuation rates, 357
Counseling experiences and beliefs, Norplant implants, 285
Cu-Fix IUD, 197

Delivery system for injectable contraceptive, Uni-Ject®, 115
Demographic dimension, the third age, 1
Depo-medroxyprogesterone acetate, 357, 363
Discontinuation rates, effect of pre-treatment counseling, 357

Early experience, Norplant implants, 345
Endometrium,
  effect of levonorgestrel, 97
  effect of RU 486, 127
Epidemiological dimension, the third age, 1
Epidemiological studies, OCs use, 135
Estradiol cypionate + medroxyprogesterone acetate, 115
Ethical dimension, the third millennium, 1
Ethinylestradiol, pharmacokinetics (rabbit), 307
Ethinylestradiol + desogestrel, 85, 109, 163
Ethinylestradiol + gestodene, 75, 85, 163
Ethinylestradiol bioavailability, effect of grapefruit juice, 41

Gemeprost + mifepristone, pregnancy termination, 281
Grapefruit juice, effect on bioavailability of ethinylestradiol, 41

Hemostatic parameters, effect of ethinylestradiol + gestodene, 75
Hormonal effects,
  ethinylestradiol + desogestrel, 163
  ethinylestradiol + gestodene, 163

Immunoglobulin levels, depo-medroxyprogesterone acetate, 363
Implant contraceptive,
  levonorgestrel, 33, 91, 97, 101, 159, 177, 285, 345
  nomegestrol acetate, 37, 121
Induced abortions, follow-up study, 267
Injectable contraceptive,

© 1996 Elsevier Science Inc. All rights reserved.
655 Avenue of the Americas, New York, NY 10010

ISSN 0010-7824/96/$15.00
PII S0010-7824(96)00106-0

depo-medroxyprogesterone acetate, 357, 363
estradiol cypionate + medroxyprogesterone acetate, 115
Intrauterine device (IUD),
Cu-Fix, 197
MLCu-250, 23
TCu 380A, 17, 197, 293
IUD tailstring, rate of pelvic inflammatory disease, 25

Latex condoms, scanning electron microscopy, 49
Latex rubber condoms, 221
Lea's Shield®, vaginal barrier contraceptive, 329
Levonorgestrel,
effect on endometrium, 97
ovulation inhibition, (monkey), 55
LHRH agonist, antifertility effects (male mouse), 299
Lubrication use with condoms, 155

Magainins antimicrobial peptides, spermicidal activity (rat, human), 205
Male contraception, medical grade polyurethane vas occlusion, 275
Methotrexate + misoprostol,
early abortion, 321
safety and efficacy, 321
Methylxanthines, effect on spermatozoa (bull), 181
Mifepristone (RU 486)
Misoprostol, pregnancy termination, 237, 243
Misoprostol + mifepristone, pregnancy termination, 281
MLCu-250, use in nulligravid women, 23

Natural family planning, Billings Ovulation Method, 69
Neem seed extracts, effect on pregnancy (primate), 375
Nomegestrol acetate implant,
clinical trial, 121
effect on androgen levels, 37
Nonoxynol-9, spermicidal activity, 313
Nonoxynol-9 spermicides, 147, 353
Nonpalpable Norplant implants, removal, 159
Norplant® implants, 33, 91, 97, 101, 159, 177, 285, 345
Nulligravid women, MLCu-250 IUD, 23

OC use,
effect on cardiovascular disease risk, 9
effect on coagulation system, 255
OC users, survey on cardiovascular risk factors, 337
Occlusion of vas deferens, medical grade polyurethane, 275
Oral contraceptive (OC),
effect on androgens, 171
ethinylestradiol + desogestrel, 85, 109, 163
ethinylestradiol + gestodene, 75, 85, 163
utilization patterns, 211
Oral contraceptives and thrombotic disease, 135
Ovulation,
effect of levonorgestrel (monkey), 55
effect of RU 486 (monkey), 55
effect of RU 486 + medroxyprogesterone acetate, 193

Parous women, intrauterine contraception, 23
Pelvic inflammatory disease, effect of IUD tailstring, 25
Pharmacokinetics,
ethinylestradiol, 41
ethinyloestradiol (rabbit), 307
Polyurethane condom, 141
Polyurethane occlusion, vas deferens, 275
Postpartum contraception, 217
Postpartum IUD insertion, 17
Pregnancy,
effect of mifepristone (rat), 367
effect of neem seed extracts (primate), 375
effect of RU39411 (rat), 367
effect of tamoxifen (rat), 367
effect on coagulation system, 255
Pregnancy outcome, women in 1981 vs. 1991, 259
Pregnancy termination,
gemeprost + mifepristone, 281
methotrexate + misoprostol, 321
misoprostol, 237, 243
misoprostol + laminaria, 237
misoprostol + mifepristone, 281
misoprostol + tamoxifen, 237
Prethrombotic states in women, 255
Prostaglandin $F_{2\alpha}$, effect on spermatozoa (bull), 181
Psycho-social outcomes, induced abortions, 267

Removals, Norplant implants, 91, 159, 345
Reproductive function, effect of RU 486 (rat), 185
RU39411, effect on pregnancy (rat), 367
RU 486 (mifepristone),
effect on endometrial tissue, 127
effect on ovulation, 193
effect on pregnancy (rat), 367
effect on reproductive function (rat), 185
ovulation inhibition (monkey), 55
RU 486 + medroxyprogesterone acetate, effect on ovulation, 193

(+)-S-2-amino-6-iodoacetamidohexanoic acid, antifertility effects (rat), 247
Scanning electron microscopy, non-lubricated latex condoms, 49
Shelf life, latex rubber condoms, 221
Social dimension, the third age, 1
Spermatogenesis, effect of buserelin (mouse), 299
Spermatozoa,
effect of methylxanthines (bull), 181
effect of prostaglandin $F_{2\alpha}$ (bull), 181
Spermicidal activity,
C31G anti-microbial agent, 313
nonoxynol-9, 313

Spermicidal effect,
aloe barbadensis, 231
againins antimicrobial peptides (rat, human), 205
zinc acetate, 231
Spermicides,
effect on sperm transport and survival, 353
tolerability of preparations, 147

Tailed vs. tailless IUDs, 25
Tailstrings of IUD, rate of pelvic inflammatory disease, 25
Tamoxifen, effect on pregnancy (rat), 367
TCu 380A, 17, 197, 293
Third age, third world, third millennium, 1
Thrombotic diseases and OCs, 135
Today® Sponge spermicide, 147
Tolerability, spermicides containing nonoxynol-9, 147

UniJect®, delivery system for injectable contraceptive, 115
Uniplant implant contraceptive, 37, 121
User satisfaction, Norplant implants, 101
Utilization patterns, oral contraceptives, 211

Vaginal contraceptive, zinc acetate and aloe barbadensis (rabbit), 231
Vas deferens occlusion, medical grade polyurethane, 275

Zinc acetate, spermicidal effect, 231